Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators
Joan Ericka Flores, 1 T raditional androgenic anabolic steroids (AASs), like testosterone, have positive anabolic (bone, muscle) actions, but androgenic (virilization, acne) effects limit their use. Selective androgenic receptor modulators (SARMs), such as Ligandrol, enobosarm, and RAD-140, bind androgen receptors with tissue-selective activity that promotes anabolic actions without significant androgenic effects. Although not U.S. Food and Drug Administration approved, they are heavily promoted as AAS alternatives and are being trialed in aging and muscle-wasting disorders. Unlike AASs, which have well-recognized hepatotoxic potential, only limited human hepatic safety data are available for SARMs.
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Patients and Methods

Case 1
A previously healthy 24-year-old man presented with a 5-week history of jaundice, anorexia, nausea, lethargy, and weight loss of 5 kg. He had used a gym supplement (LGD-4033 LIGANDROL capsules) for 9 weeks, and his symptoms developed a week after its cessation. He had a history of binge drinking once a month. He was not on any regular medications and gave no previous history of liver disease.
Examination revealed normal vital signs, jaundice, and mild hepatomegaly, without peripheral stigmata The subject's bilirubin peaked at 116 μmol/L after 2 weeks, but his liver tests and creatinine normalized over 4 months (Table 1) . Rechallenge was not performed.
Case 2
A 49-year-old man presented with jaundice and itching of 5 weeks duration. His only regular medication was an antidepressant (venlafaxine) for 11 months. platelets, 347 × 10 9 /L; and R ratio of 5.0 (indicating mixed hepatocellular-cholestatic liver injury). Alcohol consumption was insignificant. Appropriate blood tests and liver imaging excluded other liver diseases and biliary obstruction. Liver histology showed moderate cholestasis with ductopenia and minimal fibrosis and inflammation, consistent with drug-induced liver injury. Venlafaxine was ceased, and he was treated with ursodiol and cholestyramine. His bilirubin peaked at 346 μmol/L but gradually improved over 2 months; all his liver tests and creatinine were completely normal when rechecked 12 months after his initial presentation (Table 2) . Rechallenge was not performed.
Results
In both cases, the supplements were sent for toxicologic analysis and were screened by ultra-high performance liquid chromatography/photodiode array and gas chromatography-mass spectrometry. The presence of SARM in both cases (Ligandrol in case 1 and RAD-140 in case 2) was confirmed, and no other contaminants were identified.
Discussion
To our knowledge, these individuals represent the first cases of significant liver injury with SARM. Mild, transient, self-limiting increases in aminotransferases were reported in clinical trials, (1) (2) (3) (4) but discontinuation due to raised ALT was rare (one case), and serious liver injury was not documented. Causality assessment scores (Roussel Uclaf Causality Assessment Method) for cases 1 and 2 were 7 and 6 points (probable), respectively. (5) The Drug Induced Liver Injury Network (DILIN) causality score was 2 (probable) for both cases, and the DILIN severity score was 2 (moderate liver injury, case 1) and 3 (moderate to severe liver injury, case 2). (6) In both cases, the presence of SARM in the supplements was confirmed and other contaminants (especially AASs) were excluded. In the first case, alcohol was a potential confounding factor, but the pattern of liver tests (ALT>AST, normal GGT) was inconsistent with alcoholic hepatitis. In the second case, it is possible that venlafaxine may have contributed; however, he had been taking this for nearly a year, whereas venlafaxine hepatotoxicity is usually seen within 1 to 3 months (https ://liver tox.nih.gov).
The liver injury in both cases is within the described spectrum of liver injury associated with AASs. While case 2 showed the more well-known cholestatic injury profile, the hepatocellular presentation of case 1 is also well described. These off-target effects question the so-called tissue selectivity of SARMs, which has been their main selling point.
Whether these cases represent the "tip of the iceberg" remains to be seen, but given the increasing popularity of SARM use, greater vigilance and reporting of potential cases is required.
